Healthcare / Diagnostics & ResearchNasdaqGM
$20.39
-0.71 (-3.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 28% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.9M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
4/9
balance/quality
Valuation
32/100
-18.4% upside
5Y CAGR
+13.3%
100/100
Data QA
78/100
SEC 83%
Sin guardar todavía.
Market Cap
$347M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.1%
↓Gross Margin
52.8%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-82.7%
FCF / Net income
2.03x
Latest source
SEC-backed
Margin decomposition
Último año: revenue $92.4M · net income $-37.7M · FCF $-76.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024SEC | 2023SEC | 2022SEC | 2021SEC | 2020SEC |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $92.4M | $92.4M | $15.9M | $6.2M | $13.2M | — | — |
| Net Income | $-37.7M | $-37.7M | $-46.3M | $-62.7M | $-190.5M | — | — |
| EBITDA | $-32.2M | $-32.2M | $-39.9M | $-35.1M | $-218.0M | — | — |
| EPS | — | — | -3.71 | -5.58 | -37.57 | — | — |
| Gross Margin | 52.8% | 52.8% | 58.2% | 19.1% | 27.5% | — | — |
| Operating Margin | -41.3% | -41.3% | -240.2% | -690.0% | -500.7% | — | — |
| Net Margin | -40.8% | -40.8% | -290.6% | -1019.1% | -1446.8% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.03 | — | — |
| Current Ratio | 2.97 | 2.97 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-76.4M | $-76.4M | $-29.9M | $-14.7M | $8.2M | — | — |
| Returns | |||||||
| ROE | -24.1% | -24.1% | -27.2% | -30.4% | -80.3% | — | — |
| Valuation | |||||||
| P/B | 2.18 | 2.18 | 0.41 | 0.29 | 0.61 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 479.8% | 479.8% | 158.9% | -53.2% | — | — | — |
| EPS Growth | — | — | 33.5% | 85.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+119.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.71 → n/d
Residual
+119.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.